Breast Cancer Research
We have a long-standing program of pre-clinical breast cancer research within the Kolling Institute.
Our work mainly focuses on a specific type of breast cancer called triple-negative breast cancer. This typically affects women at a younger age. It is more difficult to treat and has less favourable outcomes than other types of breast cancer.
Our team is working to develop new ways to predict how the disease will progress and new drugs to overcome resistance to chemotherapy and radiotherapy. Our research is also aimed at developing new treatments to replace chemotherapy.
Professor Rob Baxter
Emeritus Professor, Medicine,
Northern Clinical School,
Faculty of Medicine and Health
Fellow of the Australian Academy of Science
Fellow of the Australasian Association of Clinical Biochemists
Dr Janet Martin
Senior Research Fellow (honorary)
Ms Hasanthi de Silva
Senior Research Assistant
Current and recent collaborators:
Medical Oncology: Professor Fran Boyle, Mater Hospital and University of Sydney
Cancer Immunology: Dr Lisa Hedger, Faculty of Science, University of Technology, Sydney
Pharmacy: Dr Pegah Varamini, University of Sydney
Chemistry: Dr Markus Müllner, Professor Richard Payne, University of Sydney
Our research program in triple-negative breast cancer has three main aims:
- To develop a new method of predicting how the disease will progress, based on measuring different proteins or biomarkers produced by the tumours
- To develop a new drug to overcome resistance to chemotherapy and radiotherapy
- To develop a new combination drug treatment to replace chemotherapy and avoid its side-effects.
Breast Cancer Research related information
Events, News and Seminars
World-first discovery
Posted on: 30 October, 2019
Kolling Institute scientist Dr Yo Otsu and a team of researchers have discovered a unique receptor ..... Read more
Category: Research Excellence
